The Lagos State government has increased its HIV response budget to ₦1.065 billion for 2026, up from about ₦791 million. The 35% increase is intended to strengthen prevention, testing and treatment services. Folakemi Animashaun, chief executive of the Lagos State AIDS Control Agency (LSACA), announced the increase on Thursday and said the state had begun distributing antiretroviral (ARV) medicines procured by the state government. She framed the move as a step toward domestic ownership amid changing global funding conditions: “Our goal is not to replace partnerships but to build a stronger foundation for them and ensure that essential HIV services remain protected whenever external funding arrangements change”.
The mechanics of the budget increase are more consequential than the headline number. Lagos recorded 7,584 positive HIV results from 387,558 tests, alongside 156,109 negative results among pregnant and breastfeeding women and 1,166 positive results from 25,167 community-based tests. The state is not just buying drugs. It is building a procurement channel that does not depend on donors who may reallocate their budgets.
This echoes the broader shift in global health financing, where traditional donors have signalled a retreat and African governments are being pressed to fund their own responses. It also mirrors the 2020 Covid-19 period, when supply chain disruptions forced states to source essential medicines domestically for the first time.
The winners are the people living with HIV in Lagos who will receive uninterrupted treatment, and LSACA, which gains a domestic procurement mandate. The losers are the development partners who lose leverage over programme design, and the states that have not raised their own budgets and remain exposed to the next funding shock.
Bottom Line: A 35% increase is a statement of intent. The test is whether the ARVs arrive before the donor money does.



